Fig. 6

BMSCs provide bortezomib-resistance to MM cells through CXCL12γ and HSPGs. a HS5-CXCL12γKO cells show a reduced capacity to protect HMCLs from bortezomib-induced cell death. XG1 or MM1.S cells were cultured alone or co-cultured with HS5-WT or HS5-CXCL12γKO BMSCs, in the presence of bortezomib at indicated concentrations for 3 days. The viability of the MM cells was analyzed by flow cytometry. Mean ± SD of three independent experiments in triplicate is shown. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 using one-way ANOVA; b HS5-EXT1KO cells show a reduced capacity to protect HMCLs from bortezomib-induced cell death. XG1 and MM1.S cells were cultured alone or co-cultured with HS5-WT or HS5-EXT1KO BMSCs, in the presence of bortezomib at indicated concentrations for 3 days. The viability of the MM cells was analyzed by flow cytometry. Mean ± SD of three independent experiments in triplicate is shown. *P ≤ 0.05; **P ≤ 0.01 using one-way ANOVA; c HS5-CXCL12γKO and HS5-EXT1KO cells show a reduced capacity to protect primary MM cells from bortezomib-induced cell death. Primary MM cells from two patients were cultured alone or co-cultured with HS5-WT, HS5-CXCL12γKO, or HS5-EXT1KO BMSCs, in the presence of bortezomib for 3 days. The viability of the MM cells was analyzed by flow cytometry. Plot representative for two independent experiments performed in triplicate. *P ≤ 0.05; **P ≤ 0.01 using one-way ANOVA